Thus, the beneficial effects of UDCA in FTD/ALS and other neurodegenerative diseases may involve at least in part, correction to damaged VAPB-PTPIP51 tethering and ER-mitochondria signaling via inhibition of GSK3β. The gene discussed is GSK3B; the disease is frontotemporal dementia.